Beta blocker
ApprovedSmall molecule
Beta blocker is one of 235 small molecule programs targeting Catecholaminergic Polymorphic Ventricular Tachycardia. It is currently in Approved.
10
Indications
25
Total Trials
11
Active Trials
234
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Beta blocker
WWeill Medical College of Cornell University
Approved
Tykerb
GSKPreclinical
Avastin
BBio-Thera Solutions
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Voltaren
NovartisPreclinical
Tricor
JJagotec
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Failure2 trials
Glaucoma2 trials
Acute Myocardial Infarction2 trials
Influence of Beta Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction
Unknown status·—··NCT04485988·3,000 enrolled
The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction
Unknown status·—··NCT04564365·1,000 enrolled
Chronic Condition1 trial
Hemodialysis1 trial
Removal of Beta Blocker Drugs by Hemodialysis
Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 1/2·NCT03361280·8 enrolled
16 more indications
Amyloidosis1 trial
N-of-1 for Beta-Blockers in Cardiac Amyloidosis
Enrolling by invitation·WWeill Medical College of Cornell University·Phase 4·NCT05019027·20 enrolled
Quality of Life1 trial
Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm
Completed·—·Phase 4·NCT06371222·42 enrolled
Tachycardia1 trial
Breast Cancer1 trial
Long-term Use of CCB and Breast Cancer Risk
Active, not recruiting·—··NCT05972785·68,500 enrolled
Myocardial Infarction1 trial
TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"
Completed·FFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III·Phase 4·NCT03596385·8,505 enrolled
Catecholaminergic Polymorphic Ventricular Tachycardia1 trial
Randomized1 trial
Hypertensive1 trial
Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk
Recruiting·—·N/A·NCT07099677·186 enrolled
Trial1 trial
Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).
Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT05122780·120 enrolled
Coronary Atherosclerosis1 trial
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
Recruiting·—·N/A·NCT03504956·150 enrolled
Post-Operative Atrial Fibrillation1 trial
Effect of Genetic Polymorphism on the Occurrence of Post-Operative Atrial Fibrillation After CABG
Completed·—··NCT03871647·256 enrolled
Cardiac1 trial
Unspecified2 trials
A Preliminary Study for INFORMED
Enrolling by invitation·WWeill Medical College of Cornell University·Phase 4·NCT05585125·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beta blocker. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details